Pacritinib: A new agent for the management of myelofibrosis?

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 15, 2015, Pages 2381-2390

  Beauverd, Yan ^a   McLornan, Donal P ^a,b   Harrison, Claire N ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Janus kinase inhibitors; myelofibrosis; myeloproliferative disease; pacritinib; ruxolitinib; treatment

Indexed keywords

2 [1 (4 FLUOROPHENYL)ETHYLAMINO] 4 (1 METHYL 1H PYRAZOL 4 YL) 6 (2 PYRAZINYLAMINO)PYRIDINE; BUSULFAN; DANAZOL; FEDRATINIB; HYDROXYUREA; JANUS KINASE; LENALIDOMIDE; MELPHALAN; MOMELOTINIB; N,N DICYCLOPROPYL 4 [(1,5 DIMETHYL 1H PYRAZOL 3 YL)AMINO] 6 ETHYL 1,6 DIHYDRO 1 METHYLIMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDINE 7 CARBOXAMIDE; PACRITINIB; PEGINTERFERON ALPHA; RUXOLITINIB; THALIDOMIDE; 11-(2-PYRROLIDIN-1-YLETHOXY)-14,19-DIOXA-5,7,26-TRIAZATETRACYCLO(19.3.1.1(2,6).1(8,12))HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE; BRIDGED COMPOUND; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ANEMIA; ANTIPROLIFERATIVE ACTIVITY; ASTHENIA; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; ENZYME INHIBITION; FATIGUE; FEVER; HEADACHE; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); MYELOFIBROSIS; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ANTAGONISTS AND INHIBITORS; PRIMARY MYELOFIBROSIS;

BRIDGED COMPOUNDS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; JANUS KINASE 1; JANUS KINASE 2; PRIMARY MYELOFIBROSIS; PYRAZOLES; PYRIMIDINES; SPLENOMEGALY;

EID: 84942156016     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1088831     Document Type: Review

References (67)

1. Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Fourth Edition. IARC: Lyon, France, 2008
2. Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County Study, 1976-1995. Am J Hematol 1999;61:10-15
3. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61
5. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-90
6. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-405
7. Dawson MA, Bannister AJ, Gottgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009;461:819-22
8. Liu F, Zhao X, Perna F, et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 2011;19:283-94
9. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990;75:4-9
10. Cervantes F, Tassies D, Salgado C, et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: Actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991;85:124-7
11. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment. Blood 2009;113:2895-901
12. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-7
13. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: An international study of 570 patients. Leukemia 2014;28:1494-500
14. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27:1861-9
15. Vannucchi AM, Guglielmelli P, Rotunno G, et al. Mutation-enhanced international prognostic scoring system (MIPSS) for primary myelofibrosis: An AGIMM & IWG-MRT project. Blood 2014;124:Abstract 403
16. Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012;120:4168-71
17. McLornan DP, Mead AJ, Jackson G, et al. Allogeneic stem cell transplantation for myelofibrosis in 2012. Br J Haematol 2012;157:413-25
18. Cervantes F, Alvarez-Larran A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005;129:771-5
19. Tsiara SN, Chaidos A, Bourantas LK, et al. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. Acta Haematol 2007;117:156-61
20. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108:1158-64
21. Barosi G, Elliott M, Canepa L, et al. Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002;43:2301-7
22. Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010;89:1233-7
23. Petti MC, Latagliata R, Spadea T, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002;116:576-81
24. Silver RT, Vandris K, Goldman JJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: A preliminary report. Blood 2011;117:6669-72
25. Ianotto JC, Boyer-Perrard F, Gyan E, et al. Efficacy and safety of pegylatedinterferon alpha-2a in myelofibrosis: A study by the FIM and GEM French cooperative groups. Br J Haematol 2013;162:783-91
26. Tefferi A, Mesa RA, Nagorney DM, et al. Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients. Blood 2000;95:2226-33
27. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807
28. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98
29. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012;30:4098-103
30. Harrison CN, Mesa RA, Kiladjian JJ, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol 2013;162:229-39
31. Te Boekhorst P, Harrison CN, Gisslinger H, et al. A Phase 1b, openlabel, dose-finding study of ruxolitinib in patients with myelofibrosis (MF) and baseline platelet counts from 50 109/L to 99 109/L (The EXPAND Study). 56th ASH Annual Meeting & Exposition. 6-9 December 2014; San Francisco, CA
32. Griesshammer M, Vannucchi AM, Le Coutre P, et al. Safety and efficacy of ruxolitinib in patients with low platelets enrolled in a phase 3b expanded-access study in myelofibrosis (MF). 2014
33. Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 2013;6:81
34. Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 2015;Epub ahead of print
35. Kwasnicka H, Thiele J, Bueso-Ramos C, et al. Long-term intervention effects on bone marrow morphology in myelofibrosis: patients treated with ruxolitinib and best available therapy. Haematologica 2013;98(Suppl 1):Abstract S591
36. Al-Ali HK, Hubert K, Lange T, et al. Complete clinical, histopathologic and molecular remission of primary myelofibrosis with long-term treatment with the JAK1/2 inhibitor ruxolitinib Abstract 1836. 56th ASH Annual Meeting, San Fransisco, CA, USA, 2014
37. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011;86:1188-91
38. Beauverd Y, Samii K. Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation. Int J Hematol 2014;100:498-501
39. Deshpande A, Reddy MM, Schade GO, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012;26:708-15
40. Marit MR, Chohan M, Matthew N, et al. Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. PLoS One 2012;7:e43437
41. Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012;489:155-9
42. Gisslinger H, Schalling M, Gisslinger B, et al. Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis. Am J Hematol 2014;89:344-6
43. Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med 2015;372:601-12
44. Pardanani A, Lasho T, Smith G, et al. CYT387, a selective JAK1/ JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009;23:1441-5
45. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27:1322-7
46. Harrison CN, Cortes JE, Cervantes F, et al. Results of a randomized, doubleblind, placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF). Blood 2013;122(21):393
47. Zhang Q, Zhang Y, Diamond S, et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: A putative mechanism for the onset of Wernicke's encephalopathy. Drug Metab Dispos 2014;42:1656-62
48. Purandare AV, McDevitt TM, Wan H, et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia 2012;26:280-8
49. Roberts AW, Seymour JF, Burbury K, et al. BMS-911543, a selective JAK2 inhibitor: A multicenter phase 1/2a study in myelofibrosis. Blood 2013;122(21):664
50. Nakaya Y, Shide K, Niwa T, et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J 2011;1:e29
51. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-9
52. Hart S, Goh KC, Novotny-Diermayr V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011;25:1751-9
53. Singer J, Al-Fayoumi S, Ma H, et al. Comprehensive kinase profile of pacritinib, a non-myelosuppressive jak2 kinase inhibitor in phase 3 development in primary and post ET/PV myelofibrosis. Blood 2014;124:21
54. Hofmann WK, de Vos S, Komor M, et al. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002;100:3553-60
55. Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010;24:756-64
56. Vanderwerf SM, Svahn J, Olson S, et al. TLR8-dependent TNF-(alpha) overexpression in Fanconi anemia group C cells. Blood 2009;114:5290-8
57. Rhyasen GW, Bolanos L, Fang J, et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 2013;24:90-104
58. Verstovsek S, Cernohous P, Komrokji R, et al. Safety overview of phase 1-2 studies of pacritinib, a non-myelosuppressive JAK2/FLT3 inhibitor, in patients with hematological malignancies. Haematologica 2013;98:119-20
59. Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2 (V617F) inhibitor, in patients with myelofibrosis. Blood 2015;125:2649-55
60. Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2 (V617F) inhibitor, in patients with myelofibrosis. Blood 2015;125(17):2649-55
61. Mesa RA, Egyed M, Szoke A, et al. Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or postessential thrombocythemia-myelofibrosis (PET-MF). J Clin Oncol 2015;33(Suppl):Abstr LBA7006
62. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-53
63. Hopman RK, Lawrence SJ, Oh ST. Disseminated tuberculosis associated with ruxolitinib. Leukemia 2014;28:1750-1
64. Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 2014;28:225-7
65. Lee SC, Feenstra J, Georghiou PR. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. BMJ Case Rep 2014;2014
66. Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 2013;143:1478-9
67. Reilly JT, McMullin MF, Beer PA, et al. Use of JAK inhibitors in the management of myelofibrosis: A revision of the british committee for standards in haematology guidelines for investigation and management of myelofibrosis 2012. Br J Haematol 2014;167:418-20